Difluprednate: Changing the landscape of ocular pharmacology

Expert Review of Ophthalmology

Volumn 3, Issue 6, 2008, Pages 619-625

  Korenfeld, Michael ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Difluprednate; Inflammation; Intraocular pressure; Ophthalmic; Postoperative; Steroid; Surgery; Uveitis

Indexed keywords

BETAMETHASONE; BETAMETHASONE SODIUM PHOSPHATE; DIFLUPREDNATE; DUREZOL; PLACEBO; PREDNISOLONE ACETATE; UNCLASSIFIED DRUG;

ARTICLE; CATARACT EXTRACTION; CLINICAL TRIAL; CONSTIPATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMULSION; EYE INFLAMMATION; HUMAN; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; LENS IMPLANTATION; NONHUMAN; PATIENT SATISFACTION; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; REPEATED DRUG DOSE; RETINA MACULA CYSTOID EDEMA; SIDE EFFECT; SINGLE DRUG DOSE; UVEITIS;

EID: 70049111586     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.3.6.619     Document Type: Article

References (33)

1. Sanders DR, Kraff M. Steroidal and nonsteroidal anti-inflammatory agents. Effect on postsurgical inflammation and blood - aqueous humor barrier breakdown. Arch. Ophthalmol. 102(10), 1453-1456 (1984).
2. Apple DJ, Solomon KD, Tetz MR et al. Posterior capsule opacification. Surv. Ophthalmol. 37(2), 73-116 (1992).
3. Gass JD, Norton EW. Cystoid macular edema and papilledema following cataract extraction. A fluorescein fundoscopic and angiographic study. Arch. Ophthalmol. 76(5), 646-661 (1966).
4. Miyake K, Maekubo K, Miyake Y, Nishi O. Pupillary fibrin membrane: a frequent early complication after posterior chamber lens implantation in Japan. Ophthalmology 96, 1228-1233 (1989).
5. Corboy JM. Corticosteroid therapy for the reduction of postoperative inflammation after cataract extraction. Am. J. Ophthalmol. 82(6), 923-927 (1976).
6. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics (10th Edition). Hardman JG, Limbird LE, Gilman AG (Eds). McGraw - Hill, NY, USA (2001).
7. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. BMJ 320(7234), 555-558 (2000).
8. Duvall B, Kershner R. The corticosteroids. In: Ophthalmic Medications and Pharmacology (2nd Edition). Duvall B, Kershner RM (Eds). Slack Inc., NJ, USA (2005).
9. Cheung D, Sandramouli S. Management of acute elevation of IOP. Ophthalmology 110(11), 2260 (2003).
10. Abelson M, Foster S, Gupta G. Diagnosing and managing anterior uveitis. Rev. Ophthalmol. 9(6), 110-114 (2002).
11. Abelson MB, Sleeper A. Insights on anti-inflammatories. A look at what we know about the efficacy and safety of steroids and NSAIDs. Rev. Ophthalmol. 12(6), (2005).
12. Furue M, Kohno Y, Yamamoto S et al. Therapeutic guidelines for atopic dermatitis 2002. Allergol. Int. 54(1), 45-49 (2005).
13. Bikowski J. The position not the presence of the halogen in corticosteroids influences potency and side effects. J. Drugs Dermatol. 5(2), 125-130 (2006).
14. Yamaguchi M, Yasueda S, Isowaki A et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int. J. Pharm. 301, 121-128 (2005).
15. Tajika T, Shirasaki Y, Kimura M, Kida T, Sakaki H, Ohtori A. Ocular distribution and metabolism after instillation of difluprednate ophthalmic emulsion in rabbits. Presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B744, Program 2654. Fort Lauderdale, FL, USA, 6-10 May 2007.
16. Inoue J, Yamaguchi M, Sakaki H. Preclinical pharmacokinetics of difluprednate ophthalmic emulsion. Presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B741, Program 2651. Fort Lauderdale, FL, USA, 6-10 May 2007.
17. Price F. Do you welcome BAK? Weighing the toxicity risk. Ophthalmol. Management (2004).
18. Dart J. Corneal toxicity: the epithelium and stioma in iatrogenic and factitious disease. Eye 17, 886-892 (2003).
19. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr. Opin. Ophthalmol. 8(2), 134-139 (2007).
20. Abelson MB, Washburn S. The downside of tear preservatives. Rev. Ophthalmol. 9(5), 102-106 (2002).
21. Sakaki H, Mito C, Nemoto S. Preclinical toxicity of difluprednate ophthalmic emulsion. Presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B743, Program 2653. Fort Lauderdale, FL, USA, 6-10 May 2007.
22. Senju Pharmaceutical Co., Ltd. Phase I clinical study of difluprednate: single instillation study. Data on file. March 1999.
23. Senju Pharmaceutical Co., Ltd. Phase I clinical study of difluprednate: repeated instillation study. Data on file. March 1999.
24. Kida T, Takahashi H, Tsuzuki M, Tajika T, Sakaki H, Ohtori A. Difluprednate emulsion inhibits postoperative inflammation in rabbit paracentesis model. Presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B745, Program 2655. Fort Lauderdale, FL, USA, 6-10 May 2007.
25. Okumura A, Tsuzuki M, Wada T et al. Efficacy of difluprednate ophthalmic emulsion in preclinical studies of uveitis. Presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B742, Program 2652, Fort Lauderdale, FL, USA, 6-10 May 2007.
26. Senju Pharmaceutical Co., Ltd. Phase IIa study of difluprednate ophthalmic emulsion in the treatment of postoperative inflammation. Data on file. February 2002.
27. Senju Pharmaceutical Co., Ltd. Phase II exploratory study of difluprednate ophthalmic emulsion in the treatment of postoperative inflammation. Data on file. April 2004.
28. Ohno S, Mochizuki M, Usui M. A Phase III, noninferiority study of difluprednate ophthalmic emulsion (DFBA) 0.05% in the treatment of anterior uveitis. Presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B808, Program 3904. Fort Lauderdale, FL, USA, 6-10 May 2007.
29. Mochizuki M, Ohho S, Usui M et al. A Phase III, open-label, clinical study of difluprednate ophthalmic emulsion (DFBA) 0.05% in the treatment of severe refractory anterior uveitis. Presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B809, Program 3905. Fort Lauderdale, FL, USA, 6-10 May 2007.
30. Ohji M, Tano Y, Hida T. Efficacy and safety results of a Phase III study of difluprednate ophthalmic emulsion (DFBA) 0.05% in postoperative inflammation. Presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B807, Program 3903. Fort Lauderdale, FL, USA, 6-10 May 2007.
31. Korenfeld M, Silverstein S, Cooke DL, Vogel R, Crockett RS; the Difluprednate Ophthalmic Emulsion 0.05% (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J. Cataract Refract. Surg. (2009) (In Press).
32. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans. Am. Ophthalmol. Soc. 96, 557-634 (1998).
33. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular edema after phacoemulsification: relationship to blood - aqueous barrier damage and visual acuity. J. Cataract Refract. Surg. 25(11), 1492-1497 (1999).